100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44HL145783
Award Date
3/1/19
Completion Date
2/28/23
Dollars Obligated
$6.5M
Overview
Activity
7
Transactions
7
Subawards
Similar Awards
Federal Agency
National Heart Lung and Blood Institute
Awardee
Zata Pharmaceuticals, Inc. (LM1CSJF7LLS6)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01605, USA
Update #1
Update #2
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION
Posted 2/22/19
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION - ABSTRACT ZATA PHARMACEUTICALS, INC. (WORCESTER, MA) AND NYBC (NEW YORK, NY) PROPOSE TO DEVELOP A CLOSED, DISPOS- ABLE PATHOGEN REDUCTION SYSTEM (Z-SYSTEM) FOR TREATMENT OF PACKED RED BLOOD CELLS (PRBC) FOR TRANSFUSION. THE VERSATILITY OF THE PROPOSED TECHNOLOGY ALLOWS FOR SEVERAL VERSIONS OF THE Z-SYSTEMS TO BE CREATED, ADAPTED TO DIFFERENT REGULATORY ENVIRONMENTS, AND FOR TREATMENT OF WHOLE BLOOD AND ANY OF ITS COMPONENTS. HOWEVER, IN THIS APPLICATION WE FOCUS ON THE DEVELOPMENT OF A SYSTEM FOR TREATMENT OF PRBC THAT WILL BE INTEGRATED INTO THE BLOOD COLLECTION SYSTEM CURRENTLY USED IN THE USA. WE HAVE ALREADY REACHED SEVERAL CRITICAL MILESTONES IN THE DEVELOPMENT OF THE Z-SYSTEMS. SPECIFICALLY, WE HAVE: (1) DEVELOPED A DETAILED SCIENTIFIC AND PRODUCTION CONCEPT ABOUT ZATA'S ANTI-PATHOGEN COMPOUNDS (ZAP-CS) AND SYNTHESIZED 3 REPRESENTATIVES: ZD010, ZD012, AND ZD014; (2) DEMONSTRATED HIGH LOG REDUCTION OF VARIOUS PATHOGENS, INCLUDING G+ AND G- BACTERIA, ENVELOPED AND NON-ENVELOPED VIRUSES, AND PROTOZOA IN WHOLE BLOOD AND IN ITS COMPONENTS BY USING ZAP-CS AT 100-250 MM; (3) SELECTED AND USED A NON-TOXIC, BIO- COMPATIBLE QUENCHER THAT NEUTRALIZES THE RESIDUAL ZAP-CS WITHOUT CHANGING THE IN VITRO PROPERTIES OF TREATED RBC; (4) DEVELOPED EXTRACTION CARTRIDGES WHICH ENABLE THE COMPLETE REMOVAL OF ZAP-C NEUTRALIZATION PRODUCTS FROM THE TREATED RBC TO FURTHER IMPROVE SAFETY; AND (5) FILED PATENT APPLICATIONS. IN THIS COMBINED PHASE I/II PROPOSAL, WE WILL PURSUE THE FOLLOWING MILESTONES WITH THE GOAL FOR DEVELOPING OF A PATHOGEN INACTIVATION SYSTEM FOR PRBC READY FOR EVALUATION BY THE FDA FOR USE IN PHASE I CLINICAL TRIALS: YEAR 1: EXPAND ZAP-C FAMILY; OPTIMIZE AND SCALE-UP ZAP-C CHEMISTRY; SELECT OPTIMAL ZAP-C AND TREATMENT CONDITIONS ENABLING 6 LOG REDUCTION OF PATHOGENS IN RBC; FURTHER DEVELOP AND OPTIMIZE METHODS OF ANALYSIS AND QUANTIFICATION OF ZAP-CS AND THEIR QUENCHING PRODUCTS; OPTIMIZE ZAP-C DEACTIVATION AND REMOVAL FROM TREATED RBC. YEAR 2: PREPARE AND QUALIFY ANALYTICAL STANDARDS OF ZAP-CS AND THEIR QUENCHING PRODUCTS; INITIATE STABILITY STUDIES OF ZAP-C; PERFORM FULL SPECTRUM OF IN VITRO TESTS TO DEMONSTRATE PRESERVED QUALITY OF TREATED RBC; PERFORM IN VITRO AND IN VIVO ZAP-C QUENCHING PRODUCTS SAFETY STUDIES; ARRANGE INITIAL DISCUSSION WITH FDA. YEAR 3: PRODUCE Z-SYSTEM PROTOTYPES AND SELECT THE OPTIMAL SYSTEM; PREPARE SUFFICIENT NUMBER OF FINAL Z-SYSTEM PROTOTYPE AND VALIDATE ITS PERFORMANCE; INITIATE STORAGE SHELF-LIFE STUDY OF Z-SYSTEM; SUBMIT REGULATORY DOCUMENTS AND ARRANGE GMP MANUFACTURING FOR FINAL Z-SYSTEM FOR PHASE I CLINICAL TESTING. THE EXTENSIVE R & D EXPERIENCE AND CAPACITY OF NYBC IN TRANSFUSION MEDICINE AND BLOOD PRODUCT MANU- FACTURING (NYBC IN THE PAST DEVELOPED AND COMMERCIALIZED S/D-TREATED PLASMA), COMBINED WITH ZATA'S STRONG EXPERTISE IN MEDICINAL AND ANALYTICAL CHEMISTRY MAKES THE DEVELOPMENT AND COMMERCIALIZATION OF THE PROPOSED Z-SYSTEM HIGHLY FEASIBLE. AFTER CLINICAL STUDIES LEADING TO FDA APPROVAL, INITIAL MARKET FOR THE Z-SYSTEM WILL BE BLOOD CENTERS IN THE US, INCLUDING BUT NOT LIMITED TO THE NYBC FAMILY OF BLOOD CENTERS.
$0
12/6/23
Not listed
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION - ABSTRACT ZATA PHARMACEUTICALS, INC. (WORCESTER, MA) AND NYBC (NEW YORK, NY) PROPOSE TO DEVELOP A CLOSED, DISPOS- ABLE PATHOGEN REDUCTION SYSTEM (Z-SYSTEM) FOR TREATMENT OF PACKED RED BLOOD CELLS (PRBC) FOR TRANSFUSION. THE VERSATILITY OF THE PROPOSED TECHNOLOGY ALLOWS FOR SEVERAL VERSIONS OF THE Z-SYSTEMS TO BE CREATED, ADAPTED TO DIFFERENT REGULATORY ENVIRONMENTS, AND FOR TREATMENT OF WHOLE BLOOD AND ANY OF ITS COMPONENTS. HOWEVER, IN THIS APPLICATION WE FOCUS ON THE DEVELOPMENT OF A SYSTEM FOR TREATMENT OF PRBC THAT WILL BE INTEGRATED INTO THE BLOOD COLLECTION SYSTEM CURRENTLY USED IN THE USA. WE HAVE ALREADY REACHED SEVERAL CRITICAL MILESTONES IN THE DEVELOPMENT OF THE Z-SYSTEMS. SPECIFICALLY, WE HAVE: (1) DEVELOPED A DETAILED SCIENTIFIC AND PRODUCTION CONCEPT ABOUT ZATA'S ANTI-PATHOGEN COMPOUNDS (ZAP-CS) AND SYNTHESIZED 3 REPRESENTATIVES: ZD010, ZD012, AND ZD014; (2) DEMONSTRATED HIGH LOG REDUCTION OF VARIOUS PATHOGENS, INCLUDING G+ AND G- BACTERIA, ENVELOPED AND NON-ENVELOPED VIRUSES, AND PROTOZOA IN WHOLE BLOOD AND IN ITS COMPONENTS BY USING ZAP-CS AT 100-250 MM; (3) SELECTED AND USED A NON-TOXIC, BIO- COMPATIBLE QUENCHER THAT NEUTRALIZES THE RESIDUAL ZAP-CS WITHOUT CHANGING THE IN VITRO PROPERTIES OF TREATED RBC; (4) DEVELOPED EXTRACTION CARTRIDGES WHICH ENABLE THE COMPLETE REMOVAL OF ZAP-C NEUTRALIZATION PRODUCTS FROM THE TREATED RBC TO FURTHER IMPROVE SAFETY; AND (5) FILED PATENT APPLICATIONS. IN THIS COMBINED PHASE I/II PROPOSAL, WE WILL PURSUE THE FOLLOWING MILESTONES WITH THE GOAL FOR DEVELOPING OF A PATHOGEN INACTIVATION SYSTEM FOR PRBC READY FOR EVALUATION BY THE FDA FOR USE IN PHASE I CLINICAL TRIALS: YEAR 1: EXPAND ZAP-C FAMILY; OPTIMIZE AND SCALE-UP ZAP-C CHEMISTRY; SELECT OPTIMAL ZAP-C AND TREATMENT CONDITIONS ENABLING 6 LOG REDUCTION OF PATHOGENS IN RBC; FURTHER DEVELOP AND OPTIMIZE METHODS OF ANALYSIS AND QUANTIFICATION OF ZAP-CS AND THEIR QUENCHING PRODUCTS; OPTIMIZE ZAP-C DEACTIVATION AND REMOVAL FROM TREATED RBC. YEAR 2: PREPARE AND QUALIFY ANALYTICAL STANDARDS OF ZAP-CS AND THEIR QUENCHING PRODUCTS; INITIATE STABILITY STUDIES OF ZAP-C; PERFORM FULL SPECTRUM OF IN VITRO TESTS TO DEMONSTRATE PRESERVED QUALITY OF TREATED RBC; PERFORM IN VITRO AND IN VIVO ZAP-C QUENCHING PRODUCTS SAFETY STUDIES; ARRANGE INITIAL DISCUSSION WITH FDA. YEAR 3: PRODUCE Z-SYSTEM PROTOTYPES AND SELECT THE OPTIMAL SYSTEM; PREPARE SUFFICIENT NUMBER OF FINAL Z-SYSTEM PROTOTYPE AND VALIDATE ITS PERFORMANCE; INITIATE STORAGE SHELF-LIFE STUDY OF Z-SYSTEM; SUBMIT REGULATORY DOCUMENTS AND ARRANGE GMP MANUFACTURING FOR FINAL Z-SYSTEM FOR PHASE I CLINICAL TESTING. THE EXTENSIVE R & D EXPERIENCE AND CAPACITY OF NYBC IN TRANSFUSION MEDICINE AND BLOOD PRODUCT MANU- FACTURING (NYBC IN THE PAST DEVELOPED AND COMMERCIALIZED S/D-TREATED PLASMA), COMBINED WITH ZATA'S STRONG EXPERTISE IN MEDICINAL AND ANALYTICAL CHEMISTRY MAKES THE DEVELOPMENT AND COMMERCIALIZATION OF THE PROPOSED Z-SYSTEM HIGHLY FEASIBLE. AFTER CLINICAL STUDIES LEADING TO FDA APPROVAL, INITIAL MARKET FOR THE Z-SYSTEM WILL BE BLOOD CENTERS IN THE US, INCLUDING BUT NOT LIMITED TO THE NYBC FAMILY OF BLOOD CENTERS.
$1.2m
4/2/21
Not listed
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION - ABSTRACT ZATA PHARMACEUTICALS, INC. (WORCESTER, MA) AND NYBC (NEW YORK, NY) PROPOSE TO DEVELOP A CLOSED, DISPOS- ABLE PATHOGEN REDUCTION SYSTEM (Z-SYSTEM) FOR TREATMENT OF PACKED RED BLOOD CELLS (PRBC) FOR TRANSFUSION. THE VERSATILITY OF THE PROPOSED TECHNOLOGY ALLOWS FOR SEVERAL VERSIONS OF THE Z-SYSTEMS TO BE CREATED, ADAPTED TO DIFFERENT REGULATORY ENVIRONMENTS, AND FOR TREATMENT OF WHOLE BLOOD AND ANY OF ITS COMPONENTS. HOWEVER, IN THIS APPLICATION WE FOCUS ON THE DEVELOPMENT OF A SYSTEM FOR TREATMENT OF PRBC THAT WILL BE INTEGRATED INTO THE BLOOD COLLECTION SYSTEM CURRENTLY USED IN THE USA. WE HAVE ALREADY REACHED SEVERAL CRITICAL MILESTONES IN THE DEVELOPMENT OF THE Z-SYSTEMS. SPECIFICALLY, WE HAVE: (1) DEVELOPED A DETAILED SCIENTIFIC AND PRODUCTION CONCEPT ABOUT ZATA'S ANTI-PATHOGEN COMPOUNDS (ZAP-CS) AND SYNTHESIZED 3 REPRESENTATIVES: ZD010, ZD012, AND ZD014; (2) DEMONSTRATED HIGH LOG REDUCTION OF VARIOUS PATHOGENS, INCLUDING G+ AND G- BACTERIA, ENVELOPED AND NON-ENVELOPED VIRUSES, AND PROTOZOA IN WHOLE BLOOD AND IN ITS COMPONENTS BY USING ZAP-CS AT 100-250 MM; (3) SELECTED AND USED A NON-TOXIC, BIO- COMPATIBLE QUENCHER THAT NEUTRALIZES THE RESIDUAL ZAP-CS WITHOUT CHANGING THE IN VITRO PROPERTIES OF TREATED RBC; (4) DEVELOPED EXTRACTION CARTRIDGES WHICH ENABLE THE COMPLETE REMOVAL OF ZAP-C NEUTRALIZATION PRODUCTS FROM THE TREATED RBC TO FURTHER IMPROVE SAFETY; AND (5) FILED PATENT APPLICATIONS. IN THIS COMBINED PHASE I/II PROPOSAL, WE WILL PURSUE THE FOLLOWING MILESTONES WITH THE GOAL FOR DEVELOPING OF A PATHOGEN INACTIVATION SYSTEM FOR PRBC READY FOR EVALUATION BY THE FDA FOR USE IN PHASE I CLINICAL TRIALS: YEAR 1: EXPAND ZAP-C FAMILY; OPTIMIZE AND SCALE-UP ZAP-C CHEMISTRY; SELECT OPTIMAL ZAP-C AND TREATMENT CONDITIONS ENABLING 6 LOG REDUCTION OF PATHOGENS IN RBC; FURTHER DEVELOP AND OPTIMIZE METHODS OF ANALYSIS AND QUANTIFICATION OF ZAP-CS AND THEIR QUENCHING PRODUCTS; OPTIMIZE ZAP-C DEACTIVATION AND REMOVAL FROM TREATED RBC. YEAR 2: PREPARE AND QUALIFY ANALYTICAL STANDARDS OF ZAP-CS AND THEIR QUENCHING PRODUCTS; INITIATE STABILITY STUDIES OF ZAP-C; PERFORM FULL SPECTRUM OF IN VITRO TESTS TO DEMONSTRATE PRESERVED QUALITY OF TREATED RBC; PERFORM IN VITRO AND IN VIVO ZAP-C QUENCHING PRODUCTS SAFETY STUDIES; ARRANGE INITIAL DISCUSSION WITH FDA. YEAR 3: PRODUCE Z-SYSTEM PROTOTYPES AND SELECT THE OPTIMAL SYSTEM; PREPARE SUFFICIENT NUMBER OF FINAL Z-SYSTEM PROTOTYPE AND VALIDATE ITS PERFORMANCE; INITIATE STORAGE SHELF-LIFE STUDY OF Z-SYSTEM; SUBMIT REGULATORY DOCUMENTS AND ARRANGE GMP MANUFACTURING FOR FINAL Z-SYSTEM FOR PHASE I CLINICAL TESTING. THE EXTENSIVE R & D EXPERIENCE AND CAPACITY OF NYBC IN TRANSFUSION MEDICINE AND BLOOD PRODUCT MANU- FACTURING (NYBC IN THE PAST DEVELOPED AND COMMERCIALIZED S/D-TREATED PLASMA), COMBINED WITH ZATA'S STRONG EXPERTISE IN MEDICINAL AND ANALYTICAL CHEMISTRY MAKES THE DEVELOPMENT AND COMMERCIALIZATION OF THE PROPOSED Z-SYSTEM HIGHLY FEASIBLE. AFTER CLINICAL STUDIES LEADING TO FDA APPROVAL, INITIAL MARKET FOR THE Z-SYSTEM WILL BE BLOOD CENTERS IN THE US, INCLUDING BUT NOT LIMITED TO THE NYBC FAMILY OF BLOOD CENTERS.
$1.2m
4/2/21
Not listed
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION - ABSTRACT ZATA PHARMACEUTICALS, INC. (WORCESTER, MA) AND NYBC (NEW YORK, NY) PROPOSE TO DEVELOP A CLOSED, DISPOS- ABLE PATHOGEN REDUCTION SYSTEM (Z-SYSTEM) FOR TREATMENT OF PACKED RED BLOOD CELLS (PRBC) FOR TRANSFUSION. THE VERSATILITY OF THE PROPOSED TECHNOLOGY ALLOWS FOR SEVERAL VERSIONS OF THE Z-SYSTEMS TO BE CREATED, ADAPTED TO DIFFERENT REGULATORY ENVIRONMENTS, AND FOR TREATMENT OF WHOLE BLOOD AND ANY OF ITS COMPONENTS. HOWEVER, IN THIS APPLICATION WE FOCUS ON THE DEVELOPMENT OF A SYSTEM FOR TREATMENT OF PRBC THAT WILL BE INTEGRATED INTO THE BLOOD COLLECTION SYSTEM CURRENTLY USED IN THE USA. WE HAVE ALREADY REACHED SEVERAL CRITICAL MILESTONES IN THE DEVELOPMENT OF THE Z-SYSTEMS. SPECIFICALLY, WE HAVE: (1) DEVELOPED A DETAILED SCIENTIFIC AND PRODUCTION CONCEPT ABOUT ZATA'S ANTI-PATHOGEN COMPOUNDS (ZAP-CS) AND SYNTHESIZED 3 REPRESENTATIVES: ZD010, ZD012, AND ZD014; (2) DEMONSTRATED HIGH LOG REDUCTION OF VARIOUS PATHOGENS, INCLUDING G+ AND G- BACTERIA, ENVELOPED AND NON-ENVELOPED VIRUSES, AND PROTOZOA IN WHOLE BLOOD AND IN ITS COMPONENTS BY USING ZAP-CS AT 100-250 MM; (3) SELECTED AND USED A NON-TOXIC, BIO- COMPATIBLE QUENCHER THAT NEUTRALIZES THE RESIDUAL ZAP-CS WITHOUT CHANGING THE IN VITRO PROPERTIES OF TREATED RBC; (4) DEVELOPED EXTRACTION CARTRIDGES WHICH ENABLE THE COMPLETE REMOVAL OF ZAP-C NEUTRALIZATION PRODUCTS FROM THE TREATED RBC TO FURTHER IMPROVE SAFETY; AND (5) FILED PATENT APPLICATIONS. IN THIS COMBINED PHASE I/II PROPOSAL, WE WILL PURSUE THE FOLLOWING MILESTONES WITH THE GOAL FOR DEVELOPING OF A PATHOGEN INACTIVATION SYSTEM FOR PRBC READY FOR EVALUATION BY THE FDA FOR USE IN PHASE I CLINICAL TRIALS: YEAR 1: EXPAND ZAP-C FAMILY; OPTIMIZE AND SCALE-UP ZAP-C CHEMISTRY; SELECT OPTIMAL ZAP-C AND TREATMENT CONDITIONS ENABLING 6 LOG REDUCTION OF PATHOGENS IN RBC; FURTHER DEVELOP AND OPTIMIZE METHODS OF ANALYSIS AND QUANTIFICATION OF ZAP-CS AND THEIR QUENCHING PRODUCTS; OPTIMIZE ZAP-C DEACTIVATION AND REMOVAL FROM TREATED RBC. YEAR 2: PREPARE AND QUALIFY ANALYTICAL STANDARDS OF ZAP-CS AND THEIR QUENCHING PRODUCTS; INITIATE STABILITY STUDIES OF ZAP-C; PERFORM FULL SPECTRUM OF IN VITRO TESTS TO DEMONSTRATE PRESERVED QUALITY OF TREATED RBC; PERFORM IN VITRO AND IN VIVO ZAP-C QUENCHING PRODUCTS SAFETY STUDIES; ARRANGE INITIAL DISCUSSION WITH FDA. YEAR 3: PRODUCE Z-SYSTEM PROTOTYPES AND SELECT THE OPTIMAL SYSTEM; PREPARE SUFFICIENT NUMBER OF FINAL Z-SYSTEM PROTOTYPE AND VALIDATE ITS PERFORMANCE; INITIATE STORAGE SHELF-LIFE STUDY OF Z-SYSTEM; SUBMIT REGULATORY DOCUMENTS AND ARRANGE GMP MANUFACTURING FOR FINAL Z-SYSTEM FOR PHASE I CLINICAL TESTING. THE EXTENSIVE R & D EXPERIENCE AND CAPACITY OF NYBC IN TRANSFUSION MEDICINE AND BLOOD PRODUCT MANU- FACTURING (NYBC IN THE PAST DEVELOPED AND COMMERCIALIZED S/D-TREATED PLASMA), COMBINED WITH ZATA'S STRONG EXPERTISE IN MEDICINAL AND ANALYTICAL CHEMISTRY MAKES THE DEVELOPMENT AND COMMERCIALIZATION OF THE PROPOSED Z-SYSTEM HIGHLY FEASIBLE. AFTER CLINICAL STUDIES LEADING TO FDA APPROVAL, INITIAL MARKET FOR THE Z-SYSTEM WILL BE BLOOD CENTERS IN THE US, INCLUDING BUT NOT LIMITED TO THE NYBC FAMILY OF BLOOD CENTERS.
$1.2m
4/2/21
Not listed
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION
$0
9/15/20